Comments on: Genentech’s Shiny New Platform http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/ Biotech stock reviews Fri, 12 Mar 2010 16:39:42 +0000 http://wordpress.org/?v=2.3.1 By: 1 Raindrop http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-329 1 Raindrop Thu, 04 Sep 2008 15:14:08 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-329 <strong>Biotech Platforms...</strong> It is interesting to see the notion of tech platforms play out in other fields. Specifically, the biotech field is all abuzz on platforms. For example Exelixis' oncology platform built on kinase inhibitors.... Biotech Platforms…

It is interesting to see the notion of tech platforms play out in other fields. Specifically, the biotech field is all abuzz on platforms. For example Exelixis’ oncology platform built on kinase inhibitors….

]]> By: Ohad Hammer http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-286 Ohad Hammer Sun, 17 Aug 2008 21:36:20 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-286 None taken. This is exactly the point. The market is gradually embracing ADCs, which are going to be a must have in the industry. players that have validated and mature ADC technologies will become very valuable. The EXEL article will be published next weekend. None taken.
This is exactly the point. The market is gradually embracing ADCs, which are going to be a must have in the industry. players that have validated and mature ADC technologies will become very valuable.

The EXEL article will be published next weekend.

]]> By: per99 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-284 per99 Fri, 15 Aug 2008 15:44:31 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-284 no offense, ohad, but I feel like you're putting too much weight on 2-3 companies that represent a tiny niche in biotech. You deserve the credit for identifying the potential of all these monoclonal abs companies, but there's a whole universe of companies out there. I really liked it when you started writing about areas other than antibodies (SNTA,PARD). What about EXEL, do you still intend to publish an article re the company? no offense, ohad, but I feel like you’re putting too much weight on 2-3 companies that represent a tiny niche in biotech. You deserve the credit for identifying the potential of all these monoclonal abs companies, but there’s a whole universe of companies out there.
I really liked it when you started writing about areas other than antibodies (SNTA,PARD). What about EXEL, do you still intend to publish an article re the company?

]]> By: Ohad Hammer http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-281 Ohad Hammer Sat, 09 Aug 2008 10:17:24 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-281 I wish I knew the answer to that. Don't forget that to date, Immunogen's technology generated the only ADC Genentech is developing, and sounds very happy with it. Theoretically, Immunogen's linkers and drugs can be used with the THIOMAB platform, so the potential is definitely there. Ohad I wish I knew the answer to that. Don’t forget that to date, Immunogen’s technology generated the only ADC Genentech is developing, and sounds very happy with it.
Theoretically, Immunogen’s linkers and drugs can be used with the THIOMAB platform, so the potential is definitely there.

Ohad

]]> By: ihopeto http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-279 ihopeto Tue, 05 Aug 2008 22:08:21 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-279 Hi Ohad I wonder what is the effect on of the new platform on IMGN's position within Genentech? Why did DNA decide to focus on SGEN's candidates especially after the success they've had with T-DM1? Thanks N.W Hi Ohad

I wonder what is the effect on of the new platform on IMGN’s position within Genentech? Why did DNA decide to focus on SGEN’s candidates especially after the success they’ve had with T-DM1?

Thanks
N.W

]]>